New drug targets breast cancer in the brain
NCT ID NCT07177950
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests a drug called SHR-A1811 in 51 women with HER2-positive breast cancer that has spread to the brain or the lining of the brain and spinal cord. The drug is given either through a vein or directly into the spinal fluid. The goal is to see if it is safe and can shrink or control the brain tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SHR-A1811 (a drug given intravenously or into the spinal fluid)
What this could lead to
If successful, this could offer a new treatment option for people with HER2-positive breast cancer that has spread to the brain or spinal lining.
What could go wrong
This is an early-phase trial with only 51 participants, so results may not apply broadly. The drug may cause serious side effects, especially neurological toxicity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••